Aims

The positive influence of short-chain fatty acids on autoimmune diseases of the nervous system, such as MS, has been increasingly studied and confirmed in recent years (Duscha et al., 2020; Haase et al., 2021; Takewaki et al., 2020). Thus, propionate showed an immunoregulatory and neuroprotective effect in MS, which improved the disease phenotype. Similar results were also demonstrated for propionate in CIDP patients (Yoon et al., 2018). In addition, propionate was shown to have an anti-oxidative and neuroregenerative effect on Schwann cells and DRG in in vitro studies (Grüter et al., 2023a).